UNSPSC 51372904: Etonitazene hydrochloride

This classification denotes an analgesic agent with the molecular formula C22H28N4O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LD057W8P8B, chemically known as benzimidazole, 1-(2-(diethylamino)ethyl)-2-(p-ethoxybenzyl)-5-nitro-, hydrochloride, but more generally known as etonitazene hydrochloride, which bears US NIH Compound Identifier 16334. European Medicines Agency schedules etonitazene hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07334MIG.

Most nations, for tariff purposes, schedule etonitazene hydrochloride under HS 29339990. SMILES: CCN(CC)CCN1C2CCC(CC2NC1CC3CCC(CC3)OCC)[N+](=O)[O-].CL.

UNSPSC 51372904 Etonitazene hydrochloride (Commodity) does not align with the recent state and local procurement activity tagged under this code. The three most recent opportunities solicited under this category are naloxone and drug deactivation systems, a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, and generic multi-source pharmaceuticals and OTC products — none of which involve etonitazene hydrochloride, a synthetic opioid. The mismatch suggests either a tagging error in the state and local procurement system or that the code has been repurposed to capture broader pharmaceutical procurement. State and local issuers appear to be using this code descriptor to flag acquisitions related to public health drug supply and pharmaceutical distribution management, not procurement of etonitazene specifically.

Recent activity shows Seminole County, Florida (IFB 60459723LAS, due July 26, 2023) soliciting naloxone and drug deactivation systems through competitive bidding, the Texas Health and Human Services Commission (RFI HHS0017013, due April 3, 2026) gathering vendor capabilities for direct-to-manufacturer prescription programs, and the Minnesota Multistate Cooperative Purchasing Alliance (RFP S1070000015802, due March 26, 2026) establishing multi-award contracts for generic pharmaceuticals and OTC products across state and local jurisdictions including Oregon. Issuers range from single counties to multistate cooperative purchasing entities. Geographic activity is concentrated in Florida, Texas, and Minnesota. The code shows minimal recent procurement aligned with its nominal pharmaceutical classification and reflects state and local procurement systems tagging pharmaceutical supply chain and public health drug initiatives under a substance-specific code that does not match the actual work being solicited.